Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial

Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review

“…All titles and abstracts were retrieved and screened. Among the 28 records selected for full-text eligibility assessment, 18 met inclusion criteria [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] (Figure 1). The characteristics of included studies are summarized in Table 1.…”

“…In 5 publications, the SBRT boost was delivered to the primary tumor only, in 2 or 3 fractions [23,24,27,29,30]. Salazar et al delivered 22.5Gy in 3 fractions (biologically equivalent dose with alpha/beta ratio of 10 (BED10), 92.5 Gy) in patients who could safely receive SBRT after 45 Gy NFRT [23].…”

The Roles of Autophagy and Senescence in the Tumor Cell Response to Radiation

“…It is only at higher levels of irradiation (above 10 Gy) that apoptosis becomes a more pronounced response to radiotherapy (10). This is, of course, relevant to stereotactic radiation treatment, wherein multiple, precisely focused beams of radiation are delivered to patients to achieve higher effective doses to the tumor while minimizing damage to surrounding tissue (11)(12)(13). With regard to cancer treatment modalities, apoptosis or other forms of cell death are, of necessity, the desired outcomes; however, there are a number of survival mechanisms that cancer cells have employed to evade (apoptotic) cell death.…”

Predicting personalised and progressive adaptive dose escalation to gross tumour volume using knowledge-based planning models for inoperable advanced-stage non-small cell lung cancer patients treated with volumetric modulated arc therapy

“…Different techniques have been studied to facilitate dose-escalation, such as using positron emission tomography (PET) scans for contouring the boost volume [8], enabling specific targeting of volumes expected to benefit from higher doses, whilst other studies used inhomogeneous dose escalation to GTV Clinical (i.e., gross tumour volume contoured on planning CT) [9,12]. In addition, Higgins et al [13] and Doyen et al [27] studied combinations of conventional fractionation radiotherapy with stereotactic ablative body radiotherapy. Higgins et al reported that 20 Gy in two fractions following 44 Gy in 22 fraction regime was a tolerable dose [13] as no grade 3 or higher toxicities were reported whereas, Doyen et al reported that three fractions of 11 Gy were safe following 46 Gy in 23 fraction chemo-radiotherapy [27].…”

“…In addition, Higgins et al [13] and Doyen et al [27] studied combinations of conventional fractionation radiotherapy with stereotactic ablative body radiotherapy. Higgins et al reported that 20 Gy in two fractions following 44 Gy in 22 fraction regime was a tolerable dose [13] as no grade 3 or higher toxicities were reported whereas, Doyen et al reported that three fractions of 11 Gy were safe following 46 Gy in 23 fraction chemo-radiotherapy [27].…”